Citius Pharmaceuticals Inc
Research Citius Pharmaceuticals Inc (CTXR) on Bullrun: market cap USD 13.70M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCTXR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 13.70M
- Financial periodQ2 2026
- RevenueUSD 1.49M
- Net income-USD 8.86M
- Free cash flow-USD 8.68M
- Gross margin67.1%
Valuation Snapshot
latest market cap is USD 13.70M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 39.74M | -USD 26.55M | n/a | -3.38 | USD 4.25M | USD 1.81M | USD 67.55M |
| FY2024 | USD 0 | -USD 39.43M | -USD 28.20M | n/a | -5.97 | USD 3.25M | USD 262.87K | USD 70.08M |
| FY2023 | USD 0 | -USD 32.54M | -USD 29.06M | n/a | -5.57 | USD 26.48M | USD 481.25K | USD 90.83M |
| FY2022 | USD 90.00K | -USD 33.64M | -USD 28.36M | n/a | -0.23 | USD 41.71M | USD 678.23K | USD 102.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 13.70M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 17.45M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 30.91M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 120.31M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 115.51M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 224.89M | n/a | n/a | n/a |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Citius Pharmaceuticals Inc's market cap?
Citius Pharmaceuticals Inc's market capitalization is USD 13.70M.
What does Citius Pharmaceuticals Inc do?
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.